Matt Larew
Stock Analyst at William Blair
(0.29)
# 4,086
Out of 4,761 analysts
12
Total ratings
28.57%
Success rate
-32.84%
Average return
Main Sectors:
Stocks Rated by Matt Larew
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRVI Maravai LifeSciences Holdings | Downgrades: Market Perform | n/a | $4.11 | - | 1 | Nov 8, 2024 | |
| AMED Amedisys | Downgrades: Market Perform | n/a | $90.44 | - | 1 | Jul 1, 2024 | |
| DNA Ginkgo Bioworks Holdings | Downgrades: Underperform | n/a | $10.82 | - | 3 | May 10, 2024 | |
| ATR AptarGroup | Upgrades: Outperform | n/a | $146.34 | - | 1 | Apr 29, 2024 | |
| TECH Bio-Techne | Initiates: Outperform | n/a | $64.92 | - | 1 | Aug 28, 2023 | |
| AVTR Avantor | Downgrades: Market Perform | n/a | $17.30 | - | 1 | Jul 31, 2023 | |
| INNV InnovAge Holding | Downgrades: Market Perform | n/a | $3.32 | - | 2 | Sep 22, 2021 | |
| MXCT MaxCyte | Initiates: Outperform | n/a | $3.85 | - | 1 | Aug 24, 2021 | |
| TWST Twist Bioscience | Initiates: Outperform | n/a | $41.31 | - | 1 | Jun 29, 2021 |
Maravai LifeSciences Holdings
Nov 8, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $4.11
Upside: -
Amedisys
Jul 1, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $90.44
Upside: -
Ginkgo Bioworks Holdings
May 10, 2024
Downgrades: Underperform
Price Target: n/a
Current: $10.82
Upside: -
AptarGroup
Apr 29, 2024
Upgrades: Outperform
Price Target: n/a
Current: $146.34
Upside: -
Bio-Techne
Aug 28, 2023
Initiates: Outperform
Price Target: n/a
Current: $64.92
Upside: -
Avantor
Jul 31, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $17.30
Upside: -
InnovAge Holding
Sep 22, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $3.32
Upside: -
MaxCyte
Aug 24, 2021
Initiates: Outperform
Price Target: n/a
Current: $3.85
Upside: -
Twist Bioscience
Jun 29, 2021
Initiates: Outperform
Price Target: n/a
Current: $41.31
Upside: -